Literature DB >> 20646003

Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma.

L J Chi1, H T Lu, G L Li, X M Wang, Y Su, W H Xu, B Z Shen.   

Abstract

T helper type 17 (Th17) and regulatory T cells (T(reg) ) play an important role in the pathogenesis of inflammation and autoimmune disorders. Recent studies have suggested that they also had an impact on tumour immunology. However, the relationship between Th17 and T(reg) cells in the pathogenesis of bladder carcinoma is still unclear. Flow cytometry was used to analyse the numbers, phenotype and cytokine production of Th17 cells in peripheral blood and tumour tissue from bladder carcinoma patients, in parallel with analysis of T(reg) cells. The suppressor capacity of T(reg) and the potential effects of interleukin (IL)-2 on the differentiation of Th17 and T(reg) cells in vitro were studied in a T cell stimulation and suppression assays. The results were as follows: Th17 cells were enriched in the tumours of patients with bladder carcinoma compared with the peripheral blood of patients and controls; patients with bladder carcinoma had a higher proportion of T(reg) cells in peripheral blood compared with healthy controls and nearly all patients examined showed a relative enrichment of tumour-infiltrating T(reg) with respect to peripheral blood; there appeared to be an inverse relationship between tumour-infiltrating Th17 and T(reg) cells; IL-2 could convert tumour-infiltrating T(reg) cells cultured in the presence of the autologous irradiated CD3(-) fraction into Th17 cells, down-regulate forkhead box P2 expression and suppressive capacity of T(reg) cells. This study is the first to define the frequency and characteristics of Th17 cells in bladder carcinoma. We suggest that the balance between Th17 and T(reg) cells may be involved in the development or progression of bladder carcinoma.
© 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20646003      PMCID: PMC2962965          DOI: 10.1111/j.1365-2249.2010.04215.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells.

Authors:  Eva V Acosta-Rodriguez; Giorgio Napolitani; Antonio Lanzavecchia; Federica Sallusto
Journal:  Nat Immunol       Date:  2007-08-05       Impact factor: 25.606

2.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

3.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.

Authors:  Ivaylo I Ivanov; Brent S McKenzie; Liang Zhou; Carlos E Tadokoro; Alice Lepelley; Juan J Lafaille; Daniel J Cua; Dan R Littman
Journal:  Cell       Date:  2006-09-22       Impact factor: 41.582

4.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

5.  Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.

Authors:  Fumiko Ichihara; Koji Kono; Akihiro Takahashi; Hiromichi Kawaida; Hidemitsu Sugai; Hideki Fujii
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

6.  Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells.

Authors:  Eva V Acosta-Rodriguez; Laura Rivino; Jens Geginat; David Jarrossay; Marco Gattorno; Antonio Lanzavecchia; Federica Sallusto; Giorgio Napolitani
Journal:  Nat Immunol       Date:  2007-05-07       Impact factor: 25.606

7.  Depletion of CD4+CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model.

Authors:  H Hong; Y Gu; H Zhang; A K Simon; X Chen; C Wu; X-N Xu; S Jiang
Journal:  Clin Exp Immunol       Date:  2009-10-08       Impact factor: 4.330

8.  Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia.

Authors:  C Wu; S Wang; F Wang; Q Chen; S Peng; Y Zhang; J Qian; J Jin; H Xu
Journal:  Clin Exp Immunol       Date:  2009-08-11       Impact factor: 4.330

Review 9.  The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease.

Authors:  B Afzali; G Lombardi; R I Lechler; G M Lord
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

10.  The immunogenicity of colorectal cancers with high-degree microsatellite instability.

Authors:  Ayan Banerjea; Stephen A Bustin; Sina Dorudi
Journal:  World J Surg Oncol       Date:  2005-05-12       Impact factor: 2.754

View more
  20 in total

1.  Th1-, Th2-, and Th17-associated cytokine expression in hypopharyngeal carcinoma and clinical significance.

Authors:  Xuemei Chen; Junfu Wang; Rui Wang; Qinghong Su; Junwen Luan; Haiyan Huang; Peng Zhou; Jinsheng Liu; Xiaoqun Xu
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-09-21       Impact factor: 2.503

2.  Increased frequency and suppressive activity of CD127(low/-) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement.

Authors:  Samantha Drennan; Nicholas D Stafford; John Greenman; Victoria L Green
Journal:  Immunology       Date:  2013-11       Impact factor: 7.397

Review 3.  Rs-10889677 variant in interleukin-23 receptor may contribute to creating an inflammatory milieu more susceptible to bladder tumourigenesis: report and meta-analysis.

Authors:  Mohammed El-Gedamy; Zakaria El-Khayat; Hassan Abol-Enein; Afaf El-Said; Eslam El-Nahrery
Journal:  Immunogenetics       Date:  2021-03-04       Impact factor: 2.846

4.  Correlation between aryl hydrocarbon receptor and IL-17+ and Foxp3+ T-cell infiltration in bladder cancer.

Authors:  Soheila Fattahi; Monireh Karimi; Mahdi Ghatreh-Samani; Fatemeh Taheri; Hedayatollah Shirzad; Faramarz Mohammad Alibeigi; Maryam Anjomshoa; Nader Bagheri
Journal:  Int J Exp Pathol       Date:  2021-11-11       Impact factor: 1.925

5.  Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barré syndrome.

Authors:  Rong Kun Han; Yue Feng Cheng; Shan Shan Zhou; Hong Guo; Rui Dong He; Li Jun Chi; Li Ming Zhang
Journal:  J Clin Immunol       Date:  2013-11-12       Impact factor: 8.317

6.  Chronic inflammation in urothelial bladder cancer.

Authors:  Gabriella Nesi; Stefania Nobili; Tommaso Cai; Saverio Caini; Raffaella Santi
Journal:  Virchows Arch       Date:  2015-08-12       Impact factor: 4.064

Review 7.  Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer.

Authors:  Zhaowei Zhu; Zhoujun Shen; Chen Xu
Journal:  Mediators Inflamm       Date:  2012-07-02       Impact factor: 4.711

8.  Elevated osteopontin levels in mild cognitive impairment and Alzheimer's disease.

Authors:  Yuan Sun; Xue Song Yin; Hong Guo; Rong Kun Han; Rui Dong He; Li Jun Chi
Journal:  Mediators Inflamm       Date:  2013-03-14       Impact factor: 4.711

9.  Regulatory T cells in children with recently diagnosed type 1 diabetes.

Authors:  Asmaa Mohamed Zahran; Khalid Ibrahem Elsayh; Kotb Abbass Metwalley
Journal:  Indian J Endocrinol Metab       Date:  2012-11

10.  Immunomodulatory effects of total intravenous and balanced inhalation anesthesia in patients with bladder cancer undergoing elective radical cystectomy: preliminary results.

Authors:  Maria Sofra; Paola Cordiali Fei; Luana Fabrizi; Maria Elena Marcelli; Claudia Claroni; Michele Gallucci; Fabrizio Ensoli; Ester Forastiere
Journal:  J Exp Clin Cancer Res       Date:  2013-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.